A: Retatrutide is not yet FDA-approved (as of March 2026), but is available through peptide suppliers
Ethical concerns Transparency and compliance are critical to ensure ethical decisions in their use, particularly for competitive athletes
A variation in t max was observed across the groups but with no apparent association with increasing hepatic impairment (45, 36, 84 and 45 h for normal hepatic function and mild, moderate and severe hepatic impairment, respectively)
Feng SW, Chang PC, Chen HY, Hueng DY, Li YF, Huang SM
The percent of employers covering GLP-1s for conditions other than diabetes will stagnate as employers try to stabilize their health care costs
Choose semaglutide when Semaglutide is often the better starting point for users who are new to GLP-1 agonists, have concerns about side effects, prefer a simpler dose escalation schedule, or need a peptide with longer real-world track record data